Presentation of Probi’s Q1 report 2019

Probi’s report for the first quarter 2019 will be published on Monday, 29 April at 8.00 a.m. CET.

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com or https://tv.streamfabriken.com/probi-q1-2019

The presentation can also be followed via a telephone conference on the following telephone number:
Sweden: +46 8 50 55 83 69
UK: +44 33 33 00 92 72
US: +1 83 35 26 83 80

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the address given above following the presentation.

FOR FURTHER INFORMATION, CONTACT:
Henrik Lundkvist, CFO, Probi, tel +46 46 286 89 41, e-post: henrik.lundkvist@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. Probi’s vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2018, Probi had net sales of MSEK 604. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi had about 4,000 shareholders on December 31, 2018. Read more at www.probi.com. 

Tags:

About Us

Probi® is a global company focused exclusively on researching, manufacturing, and delivering probiotics for supplements and functional food. We are experts at managing stable, live bacteria from R&D through every stage of the manufacturing process and are dedicated to making the health-enhancing benefits of probiotics available to people everywhere. Our health concepts, formulations, and formats are supported by robust clinical documentation. Since our founding in 1991 at Sweden’s Lund University, Probi has expanded its operations to more than 40 markets. We hold more than 400 patents globally. Read more at www.probi.com. Probi® is a registered trademark of Probi AB.

Contacts

Subscribe

Documents & Links